Literature DB >> 27716896

Choroidal abnormalities in café-au-lait syndromes: a new differential diagnostic tool?

C Cassiman1, I Casteels1, J Jacob1, E Plasschaert2, H Brems2, K Dubron3, K V Keer1, E Legius2.   

Abstract

The best known café-au-lait syndrome is neurofibromatosis type 1 (NF1). Legius syndrome (LS) is another, rarer syndrome with café-au-lait macules (CALMs). In young patients their clinical picture is often indistinguishable. We investigated the presence of choroidal abnormalities in syndromes with CALMs as a candidate tool for a more efficient diagnosis. Thirty-four patients with NF1 (14 with a truncating mutation, 14 with a non-truncating mutation and 6 with unknown mutation) and 11 patients with LS. All patients underwent an ophthalmological examination. Infrared images were performed. Choroidal nodules were diagnosed in 65% of the NF1 group. About 71% of NF1 patients with a truncating mutation and 50% of patients with a non-truncating mutation were found to have nodules. Choroidal nodules were seen in 18% of the LS patients, never more than one nodule/eye was detected in this group. Choroidal nodules are more abundantly present in NF1 genotypes with truncating mutations. In contrast, the number of choroidal nodules in LS is comparable with their presence in healthy individuals. Especially at an early age, when the clinical picture is incomplete, the detection of choroidal nodules is of diagnostic value, and helps in an appropriate genetic counselling and follow-up. These results support the suggestion to include choroidal nodules to the diagnostic criteria for NF1.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Legius syndrome; Noonan syndrome with multiple lentigines; café-au-lait macules; choroidal abnormalities; neurofibromatosis

Mesh:

Substances:

Year:  2016        PMID: 27716896     DOI: 10.1111/cge.12873

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  5 in total

Review 1.  Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants.

Authors:  Hildegard Kehrer-Sawatzki; David N Cooper
Journal:  Hum Genet       Date:  2021-12-20       Impact factor: 4.132

2.  Clinical Characteristics and Mutation Spectrum of Neurofibromatosis Type 1 in 27 Turkish Families.

Authors:  Shahrashoub Sharifi; Tuğba Kalaycı; Şükrü Palanduz; Şükrü Öztürk; Kıvanç Cefle
Journal:  Balkan Med J       Date:  2021-11       Impact factor: 2.021

3.  Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.

Authors:  Eric Legius; Ludwine Messiaen; Pierre Wolkenstein; Patrice Pancza; Susan M Huson; D Gareth Evans; Scott R Plotkin; Robert A Avery; Yemima Berman; Jaishri Blakeley; Dusica Babovic-Vuksanovic; Karin Soares Cunha; Rosalie Ferner; Michael J Fisher; Jan M Friedman; David H Gutmann; Hildegard Kehrer-Sawatzki; Bruce R Korf; Victor-Felix Mautner; Sirkku Peltonen; Katherine A Rauen; Vincent Riccardi; Elizabeth Schorry; Anat Stemmer-Rachamimov; David A Stevenson; Gianluca Tadini; Nicole J Ullrich; David Viskochil; Katharina Wimmer; Kaleb Yohay
Journal:  Genet Med       Date:  2021-05-19       Impact factor: 8.822

4.  Prevalence of Choroidal Abnormalities and Lisch Nodules in Children Meeting Clinical and Molecular Diagnosis of Neurofibromatosis Type 1.

Authors:  Mariana Flores Pimentel; Anna Heath; Michael J Wan; Rowaida Hussein; Kate E Leahy; Heather MacDonald; Erika Tavares; Cynthia VandenHoven; Katelyn MacNeill; Peter Kannu; Patricia C Parkin; Elise Heon; Arun Reginald; Ajoy Vincent
Journal:  Transl Vis Sci Technol       Date:  2022-02-01       Impact factor: 3.283

5.  Choroidal Abnormalities in Pediatric NF1: A Cohort Natural History Study.

Authors:  Eleonora Cosmo; Luisa Frizziero; Giacomo Miglionico; Chiara Sofia De Biasi; Marisa Bruno; Eva Trevisson; Ilaria Gabbiato; Giulia Midena; Raffaele Parrozzani
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.